{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:49:04Z","timestamp":1775645344443,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["NET-2016-02361805"],"award-info":[{"award-number":["NET-2016-02361805"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.coph.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T06:12:55Z","timestamp":1634019175000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["New trends in pharmacological control of neuropsychiatric symptoms of dementia"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5846-7058","authenticated-orcid":false,"given":"Damiana","family":"Scuteri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-0697","authenticated-orcid":false,"given":"Maria Tiziana","family":"Corasaniti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Nicotera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-6218","authenticated-orcid":false,"given":"Giacinto","family":"Bagetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.09.002_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13195-020-00701-7","article-title":"Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers-results from the DELCODE study","volume":"12","author":"Sannemann","year":"2020","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.coph.2021.09.002_bib2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.trci.2017.07.001","article-title":"Neuropsychiatric signs and symptoms of Alzheimer's disease: new treatment paradigms","volume":"3","author":"Lanct\u00f4t","year":"2017","journal-title":"Alzheimer's Dementia: Translational Research & Clinical Interventions"},{"key":"10.1016\/j.coph.2021.09.002_sref3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3233\/JAD-160979","article-title":"The Mild behavioral impairment checklist (MBI-C): a rating Scale for neuropsychiatric symptoms in pre-dementia populations","volume":"56","author":"Ismail","year":"2017","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.coph.2021.09.002_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jagp.2020.07.011","article-title":"The role of neuropsychiatric symptoms in research diagnostic criteria for neurodegenerative diseases","volume":"29","author":"Cummings","year":"2021","journal-title":"Am J Geriatr Psychiatr"},{"key":"10.1016\/j.coph.2021.09.002_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.09.002_sref6","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamapsychiatry.2017.0660","article-title":"Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study","volume":"74","author":"Singh-Manoux","year":"2017","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.coph.2021.09.002_sref7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41398-021-01269-y","article-title":"Late-life depression and increased risk of dementia: a longitudinal cohort study","volume":"11","author":"Ly","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.coph.2021.09.002_bib8","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.4103\/1673-5374.237125","article-title":"Evidence for accuracy of pain assessment and painkillers utilization in neuropsychiatric symptoms of dementia in Calabria region, Italy","volume":"13","author":"Scuteri","year":"2018","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.coph.2021.09.002_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.11138\/FNeur\/2017.32.4.229","article-title":"The need for better access to pain treatment: learning from drug consumption trends in the USA","volume":"22","author":"Scuteri","year":"2017","journal-title":"Funct Neurol"},{"key":"10.1016\/j.coph.2021.09.002_sref10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00228-020-02995-w","article-title":"Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia","volume":"77","author":"Scuteri","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.coph.2021.09.002_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/01.wnl.0000223333.42368.f1","article-title":"Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment","volume":"67","author":"Cummings","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2021.09.002_bib12","article-title":"Memantine for dementia","volume":"3","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.09.002_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","article-title":"Drug repositioning and repurposing for Alzheimer disease","volume":"16","author":"Ballard","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.coph.2021.09.002_bib14","first-page":"12","article-title":"Depression in Alzheimer's disease: a Delphi consensus on etiology, risk factors, and clinical management","author":"Ag\u00fcera-Ortiz","year":"2021","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.coph.2021.09.002_bib15","doi-asserted-by":"crossref","first-page":"590045","DOI":"10.3389\/fmolb.2020.590045","article-title":"Network simulations reveal molecular signatures of vulnerability to age-dependent stress and tau accumulation","volume":"7","author":"Hoffman","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.coph.2021.09.002_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2020.00279","article-title":"Pathways connecting late-life depression and dementia","volume":"11","author":"Linnemann","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2021.09.002_bib17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41398-019-0514-6","article-title":"Mechanisms and treatment of late-life depression","volume":"9","author":"Alexopoulos","year":"2019","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.coph.2021.09.002_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/npp.2016.199","article-title":"Inflammation, glutamate, and glia: a trio of trouble in mood disorders","volume":"42","author":"Haroon","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2021.09.002_bib19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.it.2020.02.002","article-title":"Neuroimmune connections in aging and neurodegenerative diseases","volume":"41","author":"Scheiblich","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.coph.2021.09.002_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neurobiolaging.2018.12.019","article-title":"Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline","volume":"76","author":"Taipa","year":"2019","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.coph.2021.09.002_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/jnr.20752","article-title":"Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell death in rats","volume":"83","author":"Tanaka","year":"2006","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.coph.2021.09.002_bib22","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101064","article-title":"Systemic inflammation impairs microglial A\u03b2 clearance through NLRP3 inflammasome","volume":"38","author":"Tejera","year":"2019","journal-title":"EMBO J"},{"key":"10.1016\/j.coph.2021.09.002_bib23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WNR.0000000000001489","article-title":"Targeting NLRP3 inflammasome improved the neurogenesis and post-stroke cognition in a mouse model of photothrombotic stroke","volume":"31","author":"Li","year":"2020","journal-title":"Neuroreport"},{"key":"10.1016\/j.coph.2021.09.002_bib24","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1007\/s12035-015-9408-7","article-title":"Stress-induced depressive behaviors require a functional NLRP3 inflammasome","volume":"53","author":"Alcocer-G\u00f3mez","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.coph.2021.09.002_bib25","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1038\/sj.npp.1301649","article-title":"Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system","volume":"33","author":"Godbout","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2021.09.002_bib26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/npp.2014.218","article-title":"Regulation of extrasynaptic glutamate levels as a pathophysiological mechanism in disorders of motivation and addiction","volume":"40","author":"McCullumsmith","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2021.09.002_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170825","article-title":"Prophylactic versus therapeutic fingolimod: restoration of presynaptic defects in mice suffering from experimental autoimmune encephalomyelitis","volume":"12","author":"Bonfiglio","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.09.002_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12929-021-00742-6","article-title":"Inflammatory signaling mechanisms in bipolar disorder","volume":"28","author":"Jones","year":"2021","journal-title":"J\u00a0Biomed Sci"},{"key":"10.1016\/j.coph.2021.09.002_bib29","article-title":"The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response","author":"Kadriu","year":"2019","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.coph.2021.09.002_bib30","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/M19-3887","article-title":"Benefits and harms of prescription drugs and supplements for treatment of clinical alzheimer-type dementia","volume":"172","author":"Fink","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2021.09.002_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00596","article-title":"The use of risperidone in behavioral and psychological symptoms of dementia: a review of Pharmacology, clinical evidence, regulatory approvals, and off-label use","volume":"11","author":"Yunusa","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2021.09.002_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.coph.2021.09.002_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10654-020-00643-2","article-title":"Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes","volume":"36","author":"Mueller","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.coph.2021.09.002_bib34","first-page":"Cd008191","article-title":"Antidepressants for agitation and psychosis in dementia","author":"Seitz","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.09.002_bib35","first-page":"Cd003944","article-title":"Antidepressants for treating depression in dementia","volume":"8","author":"Dudas","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.09.002_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coph.2021.09.002_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14283\/jpad.2018.30","article-title":"Pimavanserin in Alzheimer's disease psychosis: efficacy in patients with more pronounced psychotic symptoms","volume":"6","author":"Ballard","year":"2019","journal-title":"J\u00a0Prev Alzheimers Dis"},{"key":"10.1016\/j.coph.2021.09.002_bib38","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/13543784.2016.1193155","article-title":"Investigational drugs for treating agitation in persons with dementia","volume":"25","author":"Garay","year":"2016","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.coph.2021.09.002_bib39","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","article-title":"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients","volume":"159","author":"Pollock","year":"2002","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.coph.2021.09.002_bib40","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","article-title":"A\u00a0double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia","volume":"15","author":"Pollock","year":"2007","journal-title":"Am J Geriatr Psychiatr"},{"key":"10.1016\/j.coph.2021.09.002_bib41","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.coph.2021.09.002_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpsychires.2015.12.005","article-title":"Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease","volume":"74","author":"Newell","year":"2016","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.coph.2021.09.002_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","article-title":"Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD study","volume":"173","author":"Leonpacher","year":"2016","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.coph.2021.09.002_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098426","article-title":"Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial","volume":"9","author":"Drye","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.09.002_bib45","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1017\/S1041610211000743","article-title":"Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study","volume":"23","author":"Barak","year":"2011","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.coph.2021.09.002_bib46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am J Geriatr Psychiatr"},{"key":"10.1016\/j.coph.2021.09.002_bib47","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial","volume":"314","author":"Cummings","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.coph.2021.09.002_bib48","first-page":"316","article-title":"Microdosing psychedelics as cognitive and emotional enhancers","volume":"7","author":"Rifkin","year":"2020","journal-title":"Psychology of Consciousness: Theory, Research, and Practice"},{"key":"10.1016\/j.coph.2021.09.002_bib49","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/d41573-021-00087-7","article-title":"Will psychedelics be 'a revolution in psychiatry'?","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2021.09.002_sref50","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.09.002_bib51","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.biopsych.2009.04.029","article-title":"Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression","volume":"66","author":"Price","year":"2009","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.coph.2021.09.002_bib52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.09.002_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/02698811211026426","article-title":"Ketamine's effect on inflammation and kynurenine pathway in depression: a systematic review","author":"Kopra","year":"2021","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.coph.2021.09.002_sref54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.09.002_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13195-020-00620-7","article-title":"The cholinergic system in subtypes of Alzheimer's disease: an in\u00a0vivo longitudinal MRI study","volume":"12","author":"Machado","year":"2020","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.coph.2021.09.002_sref56","first-page":"2755","article-title":"Alzheimer's Disease Neuroimaging I: molecular properties underlying regional vulnerability to Alzheimer's disease pathology","volume":"141","author":"Grothe","year":"2018","journal-title":"Brain"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:55:38Z","timestamp":1761461738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221001429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":56,"alternative-id":["S1471489221001429"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.09.002","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New trends in pharmacological control of neuropsychiatric symptoms of dementia","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}